Monitoring of treatment in sickle cell anemia

Slides:



Advertisements
Similar presentations
Update of Anemia management in chronic kidney disease What is still missing.
Advertisements

Sickle Cell Disease Core Concepts for the Emergency Physician and Nurse Epidemiology, Genetics, Pathophysiology Spring 2013 Paula Tanabe, PhD, RN, FAEN,
1 Rash and Low T2* MRI in a Paediatric Thalassaemia Patient.
Sickle Cell Anemia Columbia County Medical Assistant Association.
Non-Transfusion-Dependent Thalassemia
JNC 8 Guidelines….
Slide 1 of 16 Dose Titration in a Patient with Myelodysplastic Syndromes.
National Institute for Health and Clinical Excellence.
Sickle Cell Disease: Core Concepts for the Emergency Physician and Nurse Acute Chest Syndrome Spring 2013.
What You Need to Know About Acute Chest Syndrome By Susan Hernandez, RN, CNN, BSN, and G. Elaine Patterson, RN-C, EdD, MA, Med, FPN-C Nursing2009, June.
Sickle Cell Disease: Core Concepts for the Emergency Physician and Nurse Acute Chest Syndrome Case Study David M. Cline, MD Wake Forest School of Medicine.
Tessa Bandhan. Question 1 A 3 year old girl known to have sickle cell disease (Hb SS) presents to the Emergency Room with a 2 day history of weakness.
Prepared by: Dr. Mazen Basheikh
The Many Faces of Hydroxyurea Soheir Adam, MD. Sickle Cell Disease The commonest genetic disorder in the US Affects about 75,000 individuals Single genetic.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Sickle Cell Disease. Group of genetic disorders characterized by: Hemolytic anemia - not enough red blood cells in the blood Vasculopathy - disorder of.
APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.
Objectives Pathophysiology of sickle cell disease
Clinical aspects of sickle cell and thalassaemia Dr.Beverley Robertson Consultant Haematologist NHS Grampian.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from.
Sickle Cell Disease: Core Concepts for the Emergency Physician and Nurse Acute Stroke Laura Moore, BS, RN Duke University School of Nursing Paula Tanabe,
Standards of Medical Care for Patients with Diabetes Mellitus John Guzek, MD March 2003.
Shadi Al-Ahmadi. The Presentation will include: Hypertension Dyslipidemia CVD Type 2 Diabetes-Associated Retinopathy Diabetic Periphral Neuropathy Diabetic.
Anemia Sickle Cell Anemia.
Transfusions in Sickle Cell Disease Ashley Duckett, MD MUSC June 21, 2012.
Hydroxyurea For the Management of Childhood SCD in Kenyan County Hospitals Hydroxyurea for SCD Panel.
Mariane de Montalembert, MD
Sickle Cell Anemia Murron Qualls Biology 6th. Names of Sickle Cell Anemia SCD SCA Hemoglobin SS disease (Hb SS)
Harvey Luksenburg, Ph.D. National Heart, Lung, & Blood Institute two years of the initial event. The NIH’s Role in the Prevention and Reduction of Strokes.
Epidemiology, Genetics, Pathophysiology Spring 2013
Sickle Cell Disease: New Approaches and Guidelines
Clinical epidemiology of individuals with SCD using Hydroxyurea at Muhimbili National Hospital 5 th National Quality Improvement Forum on Health & Social.
Prevalence of Bacteremia in Low Risk Patients with Sickle Cell Disease and Fever Shashidhar Marneni, MD Fellow(1 st Year) Pediatric Emergency Medicine.
AHMED KADHIM THALASSEMIA CENTER. TOPICS CASE PRESENTATION Hb SD DISEASE OSTEONECROSIS (avasculer necrosis of bone) THROMBOCYTOSIS IN Hb S PATIENT.
MANGEMENT OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.
Guidelines for Vaccinating Dialysis Patients BY: DR. JONAIDI ASSOCIATE PROF. OF INFECTIOUS DISEASES.
Hedy Smith MD, PhD Tufts Medical Center, Boston CMPAA 2016.
Hepatitis B virus infection in renal transplant recipients
Pregnancy and SCD.
Redefining Quality Care in T2DM Patients with CV Disease
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
Mansoura International Hospital Mansoura International Hospital
د.محمد حارث الساعاتي.
Management of Urinary Tract Infections Renal Block
Management of Urinary Tract Infections Renal Block
Sickle cell disease -refers to a group of disorders arising from defective genes that produce abnormal Hb molecules (HbS). -Defective genes produce abnormal.
Atrial Fibrillation in a CLL Patient Treated with Ibrutinib
Module 4 (a) Getting started on PrEP
Treatment of Latent TB Infection (LTBI)
HOPE: Heart Outcomes Prevention Evaluation study
Sickle Cell anemia  .
2017 Annual Data Report Healthy People 2020.
KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients 순천향대학교 서울병원 신장내과 R2 김윤석.
Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.
Diabetes Health Status Report
Pregnancy and SCD.
Chronic kidney disease and pre-dialysis
Hemoglobinopathies in Pregnancy
Transfusion in Sickle cell anemia
Systolic Blood Pressure Intervention Trial (SPRINT)
2018 Annual Data Report Volume 3: Healthy People 2020
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Sickle cell disease -refers to a group of disorders arising from defective genes that produce abnormal Hb molecules (HbS). -Defective genes produce abnormal.
Iron overload in Sickle Cell disease
Comprehensive Care Model: A Model for Sickle Cell Disease Management
HSCT in children with sickle cell Disease
Sickle Cell Acute Chest Syndrome
Presentation transcript:

Monitoring of treatment in sickle cell anemia Mohammadreza Bordbar, MD Pediatric Hematologist Associate professor of SUMS Qeshm island, 22 feb 2018

Introduction JAMA. 2014;312(10):1033-1048 Care for persons with SCD often lacks continuity Two SCD-specific disease-modifying treatments (HU, blood transfusion) still underutilized Up-to-date clinical guidelines is a necessity NIH-sponsored SCD guidelines, “Evidence-Based Management of Sickle Cell Disease, Expert Panel Report 2014” JAMA. 2014;312(10):1033-1048 Am Fam Physician. 2015;92(12):1069-1076

Health maintenance Prevention of invasive pneumococcal infection - oral penicillin prophylaxis at least up to age of 5 years - beyond the age of 5 if splenectomy or invasive pneumococcal infection - complete pneumococcal vaccination before discontinuation - at least 1 dose of PCV-13 in children 6-18 years with functional or anatomic asplenia

Screening for hepatitis C Screen in patients at high risk for infection (multiple transfusion)

Screening for retinopathy Dilated eye examination since the age of 10 years Rescreen every 1-2 years if NL exam

Screening for risk of stroke Screen with TCD annually starting at age 2 till the age of 16 years Consider regular transfusion in those with conditional (170-199cm/s) or elevated (≥200cm/s) TCD In asymptomatic children with SCD, no need for MRI or CT In asymptomatic adults with SCD, no need for TCD or MRI/CT Do not screen children with other SCD (S/β+ -thalassemia, HbSC)

Cardiovascular/ pulmonary screening No need for ECG screening in asymptomatic children or adults No need for PFT in asymptomatic children or adults Doppler echocardiography, NT-pro-BNP, Right heart catheterization (RHC) in symptomatic patients for screening pulmonary hypertension

American thoracic society clinical practice guideline Increased risk of mortality: Tricuspid regurgitant jet velocity (TRV) ≥ 2.5 m/second NT-pro-BNP ≥ 160 pg/ml RHC-confirmed PH (resting mean PAP ≥ 25 mm Hg) Am J Respir Crit Care Med. 2014 Mar 15; 189(6): 727–740.

Proposed algorithm for evaluation of pulmonary hypertension in SCD Am J Respir Crit Care Med. 2014 Mar 15; 189(6): 727–740.

Managing chronic complications Avascular necrosis: - if intermittent or chronic hip pain, evaluate for AVN by Hx, PE, radiography and MRI as needed - treat with analgesics - consult with physical therapy and orthopedic department

Renal complications Regular assessment of creatinine, GFR Screen annually for proteinuria with spot urine test since the age of 10 years If proteinuria > 300mg/24 hr, refer to a nephrologist for further evaluation Initiate ACE inhibitor in adults with microalbuminuria or proteinuria without other apparent cause even with NL BP Renal replacement therapy (dialysis, transplantation) if needed

Leg ulcers Standard therapy (debridement, wet to dry dressing, topical agents) Evaluate for osteomyelitis in chronic recalcitrant deep leg ulcers Treat with local or systemic antibiotics if suspicious for infection and positive wound culture

Evidence-based recommendations for use of hydroxyurea therapy JAMA. 2014;312(10):1033-1048

Adults with ≥3 moderate to severe pain crisis during a 12-mo period Pains interfering with daily activities and QOL Severe or recurrent ACS Severe symptomatic chronic anemia interfering with daily activities or QOL Adults and children with chronic kidney disease taking EPO to improve anemia Infants 9 mo or older, children and adolescents regardless of clinical severity to reduce complications (dactylitis, pain, ACS, anemia) Discontinue in pregnant or breastfeeding women

Monitoring HU therapy Laboratory tests before starting therapy: - CBC, diff; Retic count - quantitative Hb F measurement - renal and liver function tests - pregnancy test for women

Initiating HU therapy Baseline elevation of Hb F should not affect the decision to initiate HU Counselling regarding contraception in both genders of reproductive age Starting dose for adults: 15mg/kg/d round up to the nearest 500mg 5-10 mg/kg/d in adults with chronic kidney disease Starting dose for infants & children: 20mg/kg/d

Monitoring hu therapy CBC, diff & Retic count every 4wks when adjusting dosage Aim for a target ANC≥2000/µl Younger persons with lower baseline counts may safely tolerate ANC down to 1250/µl Maintain platelet ≥ 80,000/µl

If neutropenia or thrombocytopenia occurs Stop HU temporarily Monitor CBC, diff weekly Restart HU at a dose 5mg/kg/d lower dose when cytopenia recovered

Dose escalation Increase by 5mg/kg/d every 8wk Give until mild myelosuppression (ANC 2000-4000/µl) up to a maximum dose 35mg/kg/d CBC, diff & Retic count every 2-3 mo once stable dose established

Evidence-based recommendations for use of transfusion therapy JAMA. 2014;312(10):1033-1048

Symptomatic severe ACS (O2 saturation <90% despite supplemental O2) Symptomatic ACS and ↓Hb˃ 1g/dL from baseline (if baseline Hb˂ 9g/dL) Acute splenic sequestration plus severe anemia Acute stroke Hepatic sequestration Intrahepatic cholestasis Multisystem organ failure Aplastic crisis Symptomatic anemia Child with TCD≥ 200cm/s Adults and children with previous clinically overt stroke

Simple vs exchange transfusion

Evidence-based recommendations against use of transfusion Uncomplicated painful crisis Priapism Asymptomatic anemia Acute kidney injury without multi-organ failure Recurrent splenic sequestration JAMA. 2014;312(10):1033-1048

Precautions and monitoring RBC phenotype matching to at least C, E, K antigens Monitor for delayed transfusion reactions Monitoring serum ferritin quarterly T2* MRI (the optimal frequency of assessment not established) Iron chelation if confirmed iron-overload (LIC ≥ 7mg Fe/g dry weight) Med Clin N Am 101 (2017) 375–393

A summary of clinical trials in SCD (primary prevention of life-threatening infections)

primary & secondary prevention of stroke

hsct

Evidence-based strong recommendations with high-quality evidence (JAMA

Thanks for your attention